Astrazeneca plc ADR (NASDAQ:AZN) has a beta value of 0.39 and has seen 1.15 million shares traded in the recent trading session. The company, currently valued at $217.14B, closed the recent trade at $70.01 per share which meant it lost -$0.53 on the day or -0.74% during that session. The AZN stock price is -25.24% off its 52-week high price of $87.68 and 12.53% above the 52-week low of $61.24. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.7 million shares traded. The 3-month trading volume is 5.37 million shares.
The consensus among analysts is that Astrazeneca plc ADR (AZN) is Buy stock at the moment, with a recommendation rating of 1.37. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 10 have rated it as a Hold, with 8 advising it as a Buy. 0 have rated the stock as Underweight.
Astrazeneca plc ADR (NASDAQ:AZN) trade information
Sporting -0.74% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the AZN stock price touched $70.01 or saw a rise of 1.75%. Year-to-date, Astrazeneca plc ADR shares have moved -11.24%, while the 5-day performance has seen it change -1.35%. Over the past 30 days, the shares of Astrazeneca plc ADR (NASDAQ:AZN) have changed -0.56%. Short interest in the company has seen 6.92 million shares shorted with days to cover at 1.4.
Wall Street analysts have a consensus price target for the stock at $85, which means that the shares’ value could jump 17.64% from the levels at last check today.. The projected low price target is $79.0 while the price target rests at a high of $88.0. In that case, then, we find that the latest price level in today’s session is -25.7% off the targeted high while a plunge would see the stock gain -12.84% from the levels at last check today..
Astrazeneca plc ADR (AZN) estimates and forecasts
The company’s shares have gained 8.65% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 34.63% over the past 5 years. Earnings growth for 2025 is a modest 10.29% while over the next 5 years, the company’s earnings are expected to increase by 11.38%.
AZN Dividends
Astrazeneca plc ADR is expected to release its next earnings report on 2025-Apr-29 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 1.55 at a share yield of 2.21%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 2.27%.
Astrazeneca plc ADR (NASDAQ:AZN)’s Major holders
Insiders own 0.00% of the company shares, while shares held by institutions stand at 17.08% with a share float percentage of 17.09%. Investors are also buoyed by the number of investors in a company, with Astrazeneca plc ADR having a total of 1519.0 institutions that hold shares in the company. The top two institutional holders are PRICE T ROWE ASSOCIATES INC /MD/ with over 64.94 million shares worth more than $5.06 billion. As of 2024-06-30, PRICE T ROWE ASSOCIATES INC /MD/ held 4.1788% of shares outstanding.
The other major institutional holder is PRIMECAP MANAGEMENT CO/CA/, with the holding of over 42.6 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.32 billion and represent 2.7411% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund and WASHINGTON MUTUAL INVESTORS FUND . As of Mar 31, 2025 , the former fund manager holds about 0.97% shares in the company for having 25.51 shares of worth $1.79 billion while later fund manager owns 20.06 shares of worth $1.4 billion as of Mar 31, 2025 , which makes it owner of about 0.76% of company’s outstanding stock.
